



2023 YEAR IN REVIEW



WE ARE A GLOBAL PHARMACOLOGY COMMUNITY

that advances the science of drugs and therapeutics to accelerate the discovery of cures for disease.



Table of Contents

03	Executive Officer's Letter
04	Education
05	Annual Meeting
08	Membership
09	Government Affairs and Science Policy
10	ASPET Journals
11	Marketing and Communications
11	ASPET Financials

Dear Members and Partners,

On behalf of ASPET, thank you for your support during 2023. Over the past year, guided by our new Strategic Plan, the Society was able to expand existing programs, launch new initiatives and boldly go forward with new direction to make ASPET your home for pharmacology. We accomplished many firsts in 2023 thanks to your support!

First, congratulations to Namandjé Bumpus, PhD, on her historic election as the first African American President of ASPET. Under her leadership since July 2023, the Council has focused on making everyone in pharmacology feel at home at ASPET through inclusionary efforts in all aspects of the Society.



Prior to July 2023, ASPET President Mike Jarvis, PhD, FBPhS, FASPET, led the Society through many firsts. Early last year, the Council approved the first complete overhaul of the ASPET Bylaws since 1933, providing more flexibility for ASPET to evolve to meet the needs of our members. In addition, ASPET issued its first-ever member-wide Call for Volunteers and held its very first Volunteer Appreciation Reception in conjunction with our first stand-alone annual meeting in 30 years. We were very excited to attract more 1,000 attendees to the ASPET 2023 Annual Meeting in St. Louis, Mo. Efforts to promote the meeting garnered an APEX Award for the 2023 abstracts campaign – Meet Us in St. Louis.

In 2023, ASPET unveiled its 2023-2027 Strategic Plan and introduced several new initiatives to members.

- The Inclusion, Diversity, Equity and Accessibility (IDEA) Committee
- The Advocacy Action Center
- The Drug Discovery Digest e-newsletter

Along with these “firsts,” ASPET also marked a significant increase in 2023 for article submissions to our journals – *Drug Metabolism and Disposition*, *Pharmacological Reviews*, *Molecular Pharmacology*, *The Journal of Pharmacology and Experimental Therapeutics* and *Pharmacology Research & Perspectives* – with submission from more than 40 countries. In addition, ASPET membership numbers jumped by 5% compared to 2022, including nearly 800 new members joining our Society.

ASPET launched Pharmacology Awareness Week with a social media campaign to educate and inform the public about what pharmacology is and what pharmacologists do to advance the science of drugs and therapeutics to accelerate the discovery of cures for disease. As we work to educate the broader community about ASPET and pharmacology, we are eager to increase relationships with potential partners, including national and international societies, foundations and sponsors to reach others in the greater pharmacology community.

We appreciate your support over the last year and look forward to a stronger 2024.

Sincerely,

A handwritten signature in black ink, appearing to read "Dave Jackson". The signature is fluid and cursive, with a long horizontal stroke extending to the right.

Dave Jackson, MBA, CAE
ASPET Executive Officer



SUPPORT FOR YOUNG SCIENTISTS TO ATTEND ASPET 2023 ANNUAL MEETING

\$15,400

ASPET offered in prize money through the Student-Postdoc Poster Competition.

\$123,000

ASPET provided for travel awards to early-career scientists.

Education

In 2023, ASPET continued to provide educational and career resources to students, postdocs, educators and members in all career stages. ASPET expanded its resources and increased its financial support in travel awards for early-career scientists. The Inclusion, Diversity, Equity and Accessibility (IDEA) Committee, was formed as a standing committee to spearhead ASPET's initiatives to become a more inclusive community that ensures doors are open to all to participate fully in the Society.

FELLOWSHIPS

\$185,000

provided to support student stipends for the Summer Undergraduate Research Fellowships (SURF).

IDEA COMMITTEE

The IDEA task force was formally established as the Inclusion, Diversity, Equity and Accessibility (IDEA) Committee.

EDUCATION RESOURCES

A newly updated compilation of the Knowledge Objectives in Medical Pharmacology (KOs) was released.

New online modules of the Patient-Oriented Problem Solving System (POPS), in partnership with DeckChair Learning, were made available.

Annual Meeting

ASPET INITIATED EFFORTS TO DELIVER ONLINE CONTENT YEAR ROUND IN 2023.

8

FOCUS ON
PHARMACOLOGY
WEBINARS (AVERAGE
OF 92 ATTENDEES
PER WEBINAR)

4

SCIENTIFIC
ACHIEVEMENT
AWARD LECTURES

10

SPRING DIVISION
TOWN HALLS

4

FALL DIVISION
TOWN HALLS

37

ON-DEMAND
RECORDINGS FROM
ANNUAL MEETING
SESSIONS

In 2023, ASPET launched the first stand-alone annual meeting in decades. The ASPET 2023 Annual Meeting took place May 18-21, 2023 in St. Louis, Mo. The meeting received high survey marks.



97%

of survey respondents expressed high satisfaction levels about the “overall experience” of the ASPET 2023 Annual Meeting.



33
countries

and 44 U.S. states were represented by scientists with a passion for pharmacology at the ASPET 2023 Annual Meeting.

TOTAL REGISTRATIONS = 1,031

42%

of registrants were early-career scientists (students or postdocs),

45%

had never attended the ASPET Annual Meeting as part of Experimental Biology.

27% EXCEEDED ATTENDANCE EXPECTATIONS

ABSTRACTS



96%

OF SURVEY RESPONDENTS EXPRESSED SATISFACTION WITH THE “SCIENTIFIC EXCELLENCE OF THE POSTERS”

SOCIAL NETWORKING



25
networking
EVENTS OVER 4 DAYS

SESSIONS AT THE ANNUAL MEETING

49

SESSIONS



198

SPEAKERS



64.5

HOURS OF SCIENTIFIC CONTENT (sessions and posters) over 4 days










AVERAGE ATTENDANCE AT SESSIONS increased by **26%** compared to 2022 and exceeded pre-COVID ASPET sessions at 2019 by **18%**.

93%

OF SURVEY RESPONDENTS EXPRESSED SATISFACTION WITH THE “SCIENTIFIC EXCELLENCE OF SPEAKERS/SESSIONS”

DIVISIONAL INTERESTS OF REGISTRANTS

Attendees were allowed to select as many as were applicable.



SUPPORT FOR THE ASPET 2023 ANNUAL MEETING



- GENE TOOLS
- MAYO CLINIC - OPART
- ACS PUBLICATIONS
- WARREN CENTER FOR NEUROSCIENCE DRUG DISCOVERY, VANDERBILT SCHOOL OF MEDICINE
- BRITISH PHARMACOLOGICAL SOCIETY
- RAYBIOTECH
- INOTIV
- CASE WESTERN RESERVE UNIVERSITY
- MED ASSOCIATES
- BENTHAM SCIENCES
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
- UNIVERSITY OF MICHIGAN DEPARTMENT OF PHARMACOLOGY
- BOSTON UNIVERSITY
- UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO

Membership

2023 was a remarkable year for ASPET as we dedicated efforts to solidify our position as the premier professional home for pharmacology. Our focus on promoting inclusivity and diversity within the field led to transformative changes. Witnessing an impressive 5% growth in overall membership, we welcomed nearly 800 new members into the vibrant ASPET community.

In addition to expanding our membership, ASPET extended its global reach by 18%. ASPET broke barriers and fostered an environment that instills a sense of belonging, encouraging collaboration within our diverse interdisciplinary pharmacological community.



4,198
members

in 2023, which included
members from 79 countries.

IN MEMORIAM


- Suleiman Wakim Bahouth (1952-2023)
- Salvatore J. Enna (1944-2023)
- Qingcheng Mao (1964-2023)
- Ferid Murad (1936-2023)
- Bonnie F. Sloane (1944-2023)
- Donald M. Thompson (1939-2023)
- Thomas C. Westfall (1937-2023)
- Ben G. Zimmerman (1934-2023)

2023 CONTRIBUTIONS

- | | |
|--------------------|----------------------|
| ■ Susan Amara | ■ Bettie Sue Masters |
| ■ Bradley Andresen | ■ Harrison McNabb |
| ■ James Barrett | ■ Harvey Motulsky |
| ■ Namandjé Bumpus | ■ Bernhard Nausch |
| ■ Susan Gonsalves | ■ David Nelson |
| ■ Allyn Howlett | ■ Richard Okita |
| ■ Michael Iadarola | ■ Bhagwat Prasad |
| ■ David Jackson | ■ Gary Rankin |
| ■ Kenneth Jacobson | ■ Carolina Restini |
| ■ Michael Jarvis | ■ Katherine Serafine |
| ■ Emily Jutkiewicz | ■ Paula Stern |
| ■ Jonathan Katz | ■ Robert Theobald |
| ■ Igor Kissin | ■ Michael Wood |
| ■ William Lindblad | ■ Jayaych Woods |
| ■ Tarek Mahfouz | ■ Heike Wulff |
| ■ Craig Malbon | |

Government Affairs and Science Policy

In 2023, ASPET Government Affairs and Science Policy increased its engagement in alignment with the strategic plan.



ASPET visited Capitol Hill throughout the year to meet with elected officials and congressional staff and advocate for science funding, including 18 visits to the House and 16 to the Senate with ASPET members (2023 Washington Fellows and ASPET Council members) as well as in collaboration with coalitions and organizations. ASPET continues to build relationships with members of Congress.



ASPET has been monitoring and keeping abreast with all policy changes that are of interest to our members and the pharmacology community. The Society has increased its presence with larger coalitions to Congress on funding biomedical research and nonhuman primates research with 15 sign-on letters as well as 10 comment letters supported by the ASPET's Science Policy Committee.




ASPET launched new grassroots efforts to engage ASPET members in advocacy efforts. We encouraged them to become active advocates through advocacy campaigns and action alerts. In the last year, we have launched five advocacy campaigns and received 81 advocacy actions.



In an effort to bolster ASPET's Science Policy Committee's efforts in specialized areas of interest, we launched six new policy subcommittees focused on ASPET's policy interests (Animals in Research, Early Career Scientists, Drug Policy, Education and Outreach, Federal Budget and Appropriations, and ASPET's Washington Fellows Program).



To increase our advocacy education and outreach efforts, ASPET launched a bi-monthly newsletter, Advocacy Brief. The newsletter updates members on issues on Capitol Hill, news and updates from NIH and other relevant agencies and centers, as well as ASPET's latest advocacy news.



ASPET signed on to the amicus brief to argue that changes to the Chevron Doctrine would remove science from the regulatory process and upend decades of precedence.

ASPET Journals

In 2023, ASPET's journals (*DMD*, *JPET*, *MolPharm* and *PharmRev*) celebrated milestones, recognized young scientists in pharmacology and launched a pilot *JPET* Fellows Program.

DMD marked its 50th Anniversary with highlights of articles published. Starting in January 2023, with the Editorial "Celebrating 50 Years of Excellence in *DMD* Science," *DMD* Editor-in-Chief, Dr. Xinxin Ding, marked the occasion with a year-long collection of articles celebrating five decades of ASPET's *Drug Metabolism and Disposition* journal.

75

HIGHLIGHTED TRAINEE
AWARD NOMINATIONS
spotlighting emerging
scientific talent in the field
of pharmacology

10

JPET FELLOWSHIPS
served, from 4
different countries

42

DIFFERENT
COUNTRIES
submitted
manuscripts

85

EDITOR'S
CHOICE
articles
promoted

261

JOURNAL EDITORIAL
BOARD MEMBERS
from 25 countries,
providing expertise in the
peer review process

140

PRESUBMISSION
INQUIRIES
with an average 3.5-day
time to decision

28

DAYS
is the average time
for First Research
decision

81

ARTICLES
PUBLISHED
in special sections

Marketing and Communications

2023 ANNUAL MEETING MICROSITE

Overall engagement with ASPET increased significantly in 2023. Visitors to the 2023 annual meeting microsite more than doubled from 2022. In addition, followers on ASPET social media platforms grew substantially.

Jan - Dec 2023
14,390
USERS

67,230
PAGEVIEWS

30,914
SESSIONS



932
FACEBOOK ENGAGEMENTS
UP 150 %

6.1 K
FACEBOOK REACH
UP 76 %



NEARLY 1,000
LINKEDIN NEW FOLLOWERS




NEARLY 1,500
TWITTER NEW FOLLOWERS



ASPET received recognition for its 2023 abstracts marketing campaign with an APEX Award for “excellence in graphic design, editorial content and ability to achieve overall communications excellence.”

ASPET Financials

- 28% Journals
- 25% Management & General
- 17% Meeting & Events
- 13% Membership, Marketing
- 11% Education
- 3% Awards
- 2% Public Affairs
- 1% Divisions



**WE ARE A GLOBAL
PHARMACOLOGY
COMMUNITY**

that advances the science
of drugs and therapeutics
to accelerate the discovery
of cures for disease.



1801 Rockville Pike Suite #210
Rockville, MD 20852
aspet.org